Preclinical anticancer activity of cryptophycin-8

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 2, 1996, Pages 95-108

  Corbett, T H ^a   Valeriote, F A ^a   Demchik, L ^a   Polin, L ^a   Panchapor, C ^a   Pugh, S ^a   White, K ^a   Knight, J ^a   Jones, J ^a   Jones, L ^a   LoRusso, P ^a   Foster, B ^a   Wiegand, R A ^a   Lisow, L ^a   Golakoti, T ^b   Heltzel, C E ^b   Ogino, J ^b   Patterson, G M L ^b   Moore, R E ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Anticancer; Cryptophycin; Cyanophyte; Mice; Preclinical

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOPHYCIN 8; DEPSIPEPTIDE; LACTAM; LACTONE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; HUMAN; LD 50; MOUSE; MOUSE STRAIN; MULTIDRUG RESISTANCE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LACTAMS; LACTONES; LETHAL DOSE 50; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL;

EID: 0030088833     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schwartz RE, Hirsch CF, Sesin DF, et al. Pharmaceuticals from cultured algae. J Ind Microbiol 5: 113-124, 1990.
2. Hirsch CF, Liesch JM, Salvatore MJ, et al. Antifungal fermentation product and method. U.S. Patent 4,946,835, issued August 7, 1990.
3. Golakoti T. Ohtani I, Patterson GML, Moore RE, Corbett TH, Valeriote FA, Demchik L. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV 224. J Am Chem Soc 116: 4729-4737, 1994.
4. Barrow RA, Hemscheidt T, Liang J, Paik S, Moore RE, Tius MA. Total synthesis of cryptophycins. Revision of the structures of cryptophycins A and C. J Am Chem Soc 117: 2479-2490, 1995.
5. Golakoti T, Ogino J, Heltzel CE, et al. Structural determination, conformational analysis, chemical stability studies and antitumor evaluation of the cryptophycins. Isolation of eighteen new analogs from Nostoc sp. strain GSV 224. J Am Chem Soc (submitted).
6. Valeriote FA, Corbett TH, Demchik L, et al. Anticancer activity of cryptophycin analogs. Cancer Res (submitted).
7. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726, 1984.
8. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975.
9. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham, JC, Schabel Jr RM. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(5): 2660-2680, 1977.
10. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel Jr RM. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62(10): 1471-1488, 1978.
11. Schabel Jr FM, Skipper HE, Trader MW, Laster Jr WR, Griswold Jr DP, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905-922, 1983.
12. Biernat L, Polin L, Corgett T. Adaptation of mammary tumors of mice to a soft agar assay for use in drug discovery. Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract #185, Amsterdam, March 17-20, 1992.
13. Carney DN, Gazdar AR, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45: 2913-2923, 1985.
14. Tsai C-M, Chang K-T, Perng R-P, Mitsudomi T, Chen M-H, Kadoyama C, Gazdar AF. Correlation of intrinsic chemoresistance of non-small lung cancer cell lines with NER-2/neu gene expression but not with ras gene mutations. J Nat Cancer Inst 85: 897-901, 1993.
15. Corbett T, Valeriote F, LoRusso P, et al. Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacog (in press).
16. Horoszewicz JS, Leong SS, Chu TM, et al. The LNCaP cell line - a new model for studies on human prostatic carcinoma. In: Murphy GP, (ed.), Models for Prostatic Cancer. New York: Alan R. Liss Inc., 115-132, 1980.
17. Kaighn ME, Lechner JF, Babcock MS, Marnell M, Ohnuki Y, Narayan KS. The Pasadena cell lines in models for prostate cancer. New York: Alan R. Liss Inc., 85-109, 1980.
18. Iizumi T, Yazaki T, Kanon S, Kondo I, Koiso K. Establishment of a new prostatic carcinoma cell line (TSU-PR1). J Urol 137: 1304-1306, 1987.
19. Brattain MG, Fine WD, Khaled FM, Thomson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751-1756, 1981.
20. Corbett TH, Valeriote FA. Rodent models in experimental chemotherapy. In: Kallman RF, (ed.) The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations. Pergamon Press, 233-247, 1987.
21. Corbett TH, Valeriote RA, Polin L, et al. Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. In: Valeriote TH, Corbett TH, Baker LH, (eds) Cytoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. London: Kluwer Academic Publishers, 33-87, 1992.
22. Corbett T, Valeriote F, LoRusso P, et al. Screening and preclinical testing. In vivo methods: use of rodent solid tumors for drug discovery. In: Teicher BA, (ed.) Cancer Drug Discovery and Design. New York: Marcel Dekker Inc., Chap. 27 (in press).
23. LoRusso P, Wozniak AJ, Polin L, et al. Antitumor efficacy of PD115934 (NSC366140) against solid tumors of mice. Cancer Res 50: 4900-4905, 1990.
24. Corbett T., Lowchik N, Pugh S, et al. Antitumor activity of N-[[1-[[2-(diethylamino)ethyl]-amino]-9-oxo-9H - thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogues. Exp Opin Invest Drugs 3: 1281-1292, 1994.
25. Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP-56976, NSC-628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991.
26. Bissery M-C, Mathieu-Boue A, Lavelle F. Experimental antitumor activity of CPT-11 in vitro and in vivo. NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam March 17-20, 1992. Ann Oncol 3(Suppl 1): 82, 1993.